Preliminary unaudited fourth quarter and full year 2025 net product revenue of approximately $22M and $73M respectively; cash ...
While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with ...
Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency ...
Incyte recently reported positive topline results from its pivotal Phase 3 frontMIND trial, where adding tafasitamab (Monjuvi/Minjuvi) and lenalidomide to R-CHOP improved progression-free survival for ...
Rosai-Dorfman-Destombes disease (RDD) is a rare, benign histiocytic disorder, most often involving lymph nodes but showing ...
The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...
StockStory.org on MSN
Incyte (INCY) stock is up, what you need to know
What Happened? Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 3.7% in the morning session after ...
Zacks Investment Research on MSN
INCY's phase III Monjuvi study meets key goals in first-line lymphoma
Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...
A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.
Incyte said on Monday its experimental combo therapy helped patients with a type of blood cancer live longer without their ...
A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...
Incyte (INCY) stock and Xencor (XNCR) stock are in focus as jointly developed antibody drug tafasitamab succeeds in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback